A review of antenatal corticosteroid use in premature neonates in a middle-income country by Laher, A et al.
768       September 2017, Vol. 107, No. 9
RESEARCH
Neonatal mortality is a major problem worldwide, accounting for 
38% of all deaths in children aged <5 years.[1] Every year, it is esti-
mated that four million babies die in the neonatal period.[1] Preterm 
birth is the most common cause of neonatal mortality, accounting for 
28% of neonatal deaths.[1] Of great concern, 99% of neonatal deaths 
occur in low-income countries, with poverty being strongly associ-
ated with an increased risk of neonatal mortality.[1]
Africa accounts for 28% of neonatal deaths worldwide.[1] South 
Africa (SA) has had some success in reducing childhood mortality 
in recent years, but has not met the fourth Millennium Develop ment 
Goal of reducing mortality by two-thirds in children aged <5 years. [2] 
SA is one of the countries in which neonatal mortality has not 
decreased over the past 20 years.[3]
Addressing neonatal mortality is of vital importance in reducing 
childhood mortality. Specifically, reducing mortality in preterm 
neonates can be the most beneficial, as prematurity is the most 
common cause of neonatal mortality.[1]
In 1972, Liggins and Howie[4] conducted the first trial using 
antenatal corticosteroids (ANSs) for the prevention of respiratory 
distress syndrome (RDS) in preterm neonates. They noted a reduction 
in the incidence of RDS in preterm neonates whose mothers were 
given ANSs compared with preterm neonates whose mothers were 
not.[4] Since this landmark trial,[4] ANS therapy has become a 
standard of care to prevent preterm neonatal complications.[5]
A Cochrane review of 21 articles evaluating the effect of ANSs 
on preterm neonates[5] showed that ANSs reduced the risk of RDS, 
intraventricular haemorrhage (IVH), necrotising enterocolitis (NEC) 
and early-onset sepsis, reduced mortality and the need for respiratory 
support, and resulted in a trend towards reduced need for surfactant 
therapy. However, of these 21 studies, 17 were conducted in high-
income countries and only 4 in middle-income countries. [5] In 
addition to the benefits shown in the Cochrane review, there seems 
to be a beneficial effect of ANSs on symptomatic patent ductus 
arteriosus (PDA).[6]
The use of ANSs in low- and middle-income countries (LMICs) 
remains low.[7] The main reason is mothers being admitted in 
advanced labour.[8] Other reasons include inevitable abortion, 
obstetric emergencies necessitating immediate delivery, incorrect 
assessment of gestational age, refusal of hospital treatment, and 
obstetricians missing an opportunity to provide mothers with 
ANSs. [8] The latter should decrease, as the National Institute for 
Health and Care Excellence recommends routine administration of 
ANSs to women who are in suspected or established preterm labour 
at a gestational age <34 weeks.[9]
A recent article by Azad and Costello[10] suggests that caution is 
needed before increasing the use of ANSs in LMICs. They question 
the efficacy of ANSs in LMICs to improve mortality in premature 
neonates at a gestational age of <33 weeks, and state that ANSs are of 
no benefit after 33 weeks’ gestation.[10] 
Althabe et al.[11] conducted a randomised trial in six LMICs 
(Argen tina, Guatemala, India, Kenya, Pakistan and Zambia) to imple-
ment strategies to reduce neonatal mortality. Strategies included 
identifying women at risk for preterm birth and upscaling ANSs in 
these women, whereas standard practice was continued in the control 
group. These strategies resulted in an increase in ANS coverage from 
10% in the control group to 45% in the intervention group.[11] Despite 
the increase in ANS coverage, the intervention group showed an 
increase in neonatal mortality, with an excess of 3.5 neonatal deaths 
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for every 1 000 women exposed to this strategy.[11] It was not possible 
to assess the weight or gestational age of the babies in the study, and 
the cause of this increased mortality was not clear.
There is limited information on ANS use in SA. The Dexiprom 
study is the only study that has looked at effects of ANSs in SA, but 
it only involved mothers who had preterm premature rupture of 
membranes.[12] There is concern over the use of ANSs in LMICs.
Objective
To review ANS use in a hospital in SA, a middle-income country.
Methods
Study design
This was a retrospective observational study. The study population 
included all neonates with a birth weight between 500 g and 
1 800 g born at Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH) between 1 January 2013 and 30 June 2016. Exclusion 
criteria included babies with lethal birth defects and those with 
unobtainable records. The total sample was analysed and then 
divided into two groups: babies weighing ≥1 500 g and those 
weighing <1 500 g. Each of the two groups was further divided into 
an ANS-exposed group and an unexposed group, and these groups 
were then compared. The ANS-exposed group were neonates whose 
mothers were given ANS, and the ANS-unexposed group were 
those whose mothers were not. At CMJAH, two doses of 12 mg 
betamethasone 12 hours apart are given intramuscularly to mothers 
if the gestational age is <34 weeks or if the estimated fetal weight is 
<2 000 g. In this study, birth weight was used instead of gestational 
age because gestational age is not accurate in our setting, where 
antenatal ultrasound is not routinely done and patients’ recollection 
of the date of their last menstrual period is often inaccurate.
RDS is diagnosed using chest radiographs and clinically 
(tachypnoea, subcostal recessions, intercostal recessions) in pre-
mature neonates requiring oxygen at CMJAH. The use of surfactant 
and continuous positive airway pressure (CPAP) is limited to 
neonates with a birth weight of >750 g, and is at the discretion of 
the attending doctor. Early rescue surfactant is used at CMJAH. The 
combination of early rescue surfactant and CPAP has been shown to 
reduce morbidity and mortality associated with intensive care unit 
admissions at CMJAH.[13]
Data
This was a secondary review of an existing database. Neonatal records 
are kept in a neonatal database at CMJAH. Data are managed using 
Research Electronic Data Capture (REDCap)[14] which is hosted by 
the University of the Witwatersrand. Data are collected by clinicians 
using hospital records and verified at several different points. 
Permission was obtained to use this neonatal database.
Statistical analysis
Maternal and neonatal variables were evaluated. Valid cases were 
analysed and missing data excluded. Data were described using 
standard statistical methods. Categorical variables were described 
using frequencies and percentages, while continuous variables were 
described using means and standard deviations (SDs) or medians 
and interquartile ranges, depending on the distribution of the data. 
Chi-square tests were used to compare categorical variables. Student’s 
independent t-test was used to compare continuous variables with a 
normal distribution. Non-parametric tests were used for skewed data. 
The level of significance was set at p<0.05. Analysis was done using 
SPSS, version 24 (IBM, USA). Associations with the use of ANSs were 
determined using logistic regression. All variables that approached 
significance (p<0.06) on univariate analysis were explored.
Ethical approval
The study was approved by the Human Research Ethics Committee of 
the University of the Witwatersrand (ref. no. M160730).
Results
There was a total of 6 186 neonates on the REDCap database 
(accessed on 27 September 2016) between 1 January 2013 and 30 June 
2016. Of the 6 186 neonates, 3 415 had a birth weight >1 800 g and six 
a birth weight of <500 g. A further 656 were excluded (Fig. 1), result-
ing in a final sample size of 2 109. The mean (SD) birth weight of the 
final sample was 1 292.4 (323.2) g, and the mean gestational age was 
30.2 (2.9) weeks. ANS coverage of the final sample was less than half, 
with 930/2 109 neonates (44.1%) exposed to ANSs and 1 179/2 109 
(55.9%) not exposed.
Maternal characteristics
Maternal characteristics are shown in Table 1. Mothers who did not 
attend antenatal care were significantly less likely to receive ANSs 
(p<0.001). It was also observed that mothers with hypertension 
were more likely to receive ANSs (p<0.001), whereas HIV-positive 
mothers were less likely (p=0.001). There were 718/2 101 vaginal 
deliveries (34.2%) and 1 383/2 101 caesarean sections (65.8%). Vaginal 
deliveries were associated with decreased ANS coverage (p<0.001). 
There was no significant association between ANS coverage and 
maternal age, parity, chorioamnionitis or diabetes.
Neonatal characteristics
Neonatal characteristics of the total sample are shown in Table 2 and 
continuous variables in Table 3. Valid data are shown in the table and 
percentages are expressed in columns.
Gender, spontaneous gastrointestinal perforation, oxygen required 
by day 28 of life and home oxygen required were not included 
in Table 2, as none of these variables was significantly different. 
Reported associations with ANSs were included in the table, even 
though these variables were not significant in the current study.
Total sample (Table 2)
In the total sample, the variables late-onset sepsis (p=0.017), RDS 
(p<0.001), CPAP (p=0.002) and surfactant therapy (p=0.016) were 
Total sample 
N=6 186
Excluded n=4 077:
>1 800 g n=3 415
<500 g n=6
Unknown birth weight n=56
Born outside CMJAH n=543
Lethal birth defects n=16
Missing information n=5
Unknown whether ANSs issued n=36
Final sample 
n=2 109
ANS exposed 
n=930 (44.1%)
ANS unexposed 
n=1 179 (55.9%)
Fig. 1. Patient selection. (CMJAH = Charlotte Maxeke Johannesburg Aca­
demic Hospital; ANSs = antenatal steroids.)
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significantly associated with ANS exposure. However, when the total 
group was divided according to birth weight <1 500 g and ≥1 500 g, 
late-onset sepsis, RDS, CPAP and surfactant therapy were no longer 
significant. This indicates that birth weight was a major confounding 
factor.
Neonates ≥1 500 g (Tables 2 and 3)
In the subgroup weighing ≥1 500 g, there were 197/691 neonates 
(28.5%) exposed to ANSs and a survival rate of 674/690 (97.7%). 
There was a significantly lower mean birth weight (p=0.002) and 
mean gestational age (p<0.001) in neonates exposed to ANSs 
compared with those who were not exposed. It was observed that 
neonates exposed to ANSs had a longer duration of stay than 
those who were not exposed (p=0.002). There was no significant 
difference between exposure to ANSs and RDS, IVH, NEC, PDA, 
early- and late-onset sepsis, and other neonatal characteristics. The 
variables most significantly associated with ANSs using logistic 
regression (Table 4) were antenatal care (p=0.015), vaginal delivery 
(p=0.043), maternal hypertension (p=0.002), birth weight (p=0.034) 
and gestational age (p<0.001). Maternal HIV and duration of stay 
were not significant after logistic regression.
Neonates <1 500 g (Tables 2 and 3)
In the subgroup weighing <1 500 g, there were 733/1 418 neonates 
exposed to ANS (53.1%) and a survival rate of 1 075/1 418 (75.8%). 
Neonates exposed to ANSs were significantly less likely to have a PDA 
(p=0.015), to have an IVH (p=0.049), and to require resuscitation at 
birth (p<0.001). There was a significant association between exposure 
to ANSs and increased survival (p<0.001). It was also observed 
that neonates exposed to ANSs had a longer duration of stay in 
hospital than those who were not exposed (p=0.001). There was no 
significant association between ANS and RDS, NEC, early- and late-
onset sepsis and other neonatal characteristics. The variables most 
significantly associated with ANSs using logistic regression (Table 5) 
were antenatal care (p<0.001), vaginal delivery (p=0.038), multiple 
gestation (p<0.001), resuscitation at birth (p=0.001), PDA (p=0.001) 
and duration of stay (p=0.012). Variables that were not significant 
after logistic regression were conventional ventilation, IVH, outcome, 
maternal hypertension and HIV.
Discussion
The current study showed ANS coverage of 44.1% at CMJAH. This 
figure has increased since 1993, when coverage was only 20%,[8] 
but it is lower than in other LMICs, which according to the WHO 
Multicountry Survey on Maternal and Newborn Health had an average 
coverage of 52%.[15] ANS coverage at CMJAH is substantially lower than 
the average of 80% in high-income countries (HICs).[11] An increase in 
gestational age was associated with decreased exposure to ANS. This 
trend is also noted in HICs, where ANS coverage decreases by more 
than half at 34 weeks compared with coverage at 24 - 30 weeks.[16] The 
reasons for this are not clear. It may represent inaccurate gestational 
age estimation or reduced attention to ‘moderately preterm’ babies.[16]
Our study showed surprising results when the total sample was 
analysed, as certain results were significant in the total sample and 
not significant in either group when stratified by birth weight. This is 
because more small babies (51.7%), than larger babies (28.5%), were 
exposed to ANSs, showing that birth weight is a confounding factor.
In our study, vaginal delivery was associated with decreased ANS 
use. This is true in other LMICs and HICs.[15,16] The main reason for 
this decrease in ANS use is mothers presenting in advanced labour, 
giving no opportunity for ANSs to be provided.[8] We also found that 
unbooked mothers were significantly less likely to receive ANSs. 
Lack of antenatal care is consistently associated with reduced ANS 
coverage in LMICs and HICs.[15,16] This is a difficult problem to 
address, as it is probably associated with low socioeconomic status 
and poor maternal education and is a point for improvement.
In our study, maternal hypertension had an association with 
increased ANS use. This is probably because mothers with 
hypertension are followed up regularly during the antenatal period 
and are usually admitted if preterm delivery is necessary. The 
decreased ANS exposure associated with maternal HIV infection was 
an interesting observation, but cannot be explained by our study. It 
was, however, not significant on logistic regression.
We found no association between ANS exposure and RDS, NEC, 
early-onset sepsis or need for respiratory support. This contradicts 
the Cochrane review[5] on the effect of ANSs on preterm neonates, 
but Pattinson et al.[12] also showed no statistical significance in RDS, 
NEC, early-onset sepsis and need for ventilation in their study in SA. 
It must be pointed out, however, that the neonates in Pattinson et al.’s 
study had a higher mean birth weight than those in our study.
We found that neonates exposed to ANSs were less likely to have a 
PDA than those who were not exposed. This supports Salhab et al.’s[6] 
finding of a beneficial effect of ANSs on PDA. Possible mechanisms 
for this are a steroid effect on prostaglandin synthesis, reduced 
sensitivity of the ductal muscle to prostaglandin E2, and increased 
activity of the prostaglandin E2 inactivation enzyme.[6]
Table 1. Maternal characteristics associated with receiving ANSs
Variable* Total sample
≥1 500 g <1 500 g
Total ANSs No ANSs p-value Total ANSs No ANSs p-value
Antenatal care, n/N (%) 1 773/2 085 
(85.0)
587/676 
(86.8)
178/193 
(92.2)
409/483 
(84.7)
0.009 1 186/1 409 
(84.2)
668/729 
(91.6)
518/680 
(76.2)
<0.001
Maternal hypertension, 
n/N (%)
552/2 100 
(26.3)
126/685 
(18.4)
54/197 
(27.4)
72/488 
(14.8)
<0.001 426/1 415 
(30.1)
260/732 
(35.5)
166/683 
(24.3)
<0.001
Maternal HIV, n/N (%) 648/2 101 
(30.8)
227/688 
(33.0)
53/197 
(26.9)
174/491 
(35.4)
0.031 421/1 413 
(29.8)
197/731 
(26.9)
224/682 
(32.8)
0.015
Vaginal delivery, n/N (%) 718/2 101 
(34.2)
237/688 
(34.4)
52/196 
(26.5)
185/492 
(37.6)
0.006 481/1 413 
(34.0)
204/730 
(27.9)
277/683 
(40.6)
<0.001
Multiple gestation, n/N (%) 433/2 100 
(20.6)
172/689 
(25.0)
51/197 
(25.9)
121/492 
(24.6)
0.723 261/1 411 
(18.5)
114/729 
(15.6)
147/682 
(21.6)
0.004
ANSs = antenatal corticosteroids.
*N differs owing to missing data.
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Our study demonstrated a significant asso-
ciation between ANS exposure and survival 
in neonates weighing <1 500 g. This finding 
is in agreement with Pattinson et al.[12] 
and the Cochrane review on the effect of 
ANSs on preterm neonates,[5] but contrasts 
with Althabe et al.’s[11] observation of an 
increase in neonatal mortality in LMICs 
with the upscaling of ANSs and differs from 
the conclusions of Azad and Costello,[10] 
who questioned whether ANSs improve 
neonatal mortality. Our study also showed 
an association between ANS exposure and 
reduced IVH. This association was only 
significant in neonates weighing <1 500 g 
and supports the findings of the Cochrane 
review[5] that ANS exposure reduces the risk 
of IVH.
Our study demonstrated a longer duration 
of stay in both weight groups, <1 500 and 
≥1 500 g, for neonates exposed to ANSs 
compared with those who were not exposed. 
This interesting observation could be 
explained by a significantly higher survival 
rate in the ANS-exposed group, and the fact 
that the lower mean birth weight (1 236 g) 
in this group than in the unexposed group 
(1 336 g) meant that it took longer for 
the babies who had been exposed to reach 
1 600  g, the discharge weight at CMJAH. 
Most deaths at CMJAH occur within the 
first 7 days of life.
There were no associations between ANS 
exposure and improved neonatal outcomes 
in neonates weighing ≥1 500 g in our study. 
This supports Azad and Costello’s[10] obser-
vation that the use of ANSs is of no benefit 
after 33 weeks’ gestation in LMICs.
Study limitations
This was a retrospective study, and there was 
low ANS coverage. The number and timing 
of ANS doses were not known. We can only 
comment on associations and cannot address 
effects of ANSs in LMICs. Since birth weight 
instead of gestational age was used, babies 
with intrauterine growth restriction may 
have been included in our sample.
Conclusions
Preterm birth is associated with multiple 
complications. There have recently been 
questions on the efficacy of ANSs in LMICs. 
The present study showed an association 
between ANSs and increased survival, 
decreased PDA and decreased IVH in neo-
nates weighing <1 500 g. However, there 
was no association between ANSs and RDS, 
NEC or sepsis, and there were no asso-
ciations with improved neonatal outcome in 
neonates weighing ≥1 500 g. This suggests a 
review of the birth weight cut-off point for 
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issuing ANSs in our setting, and perhaps indicates a need for a ran-
domised controlled trial on the effects of ANSs in LMICs.
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Table 3. Continuous variables associated with ANS exposure
Variable
≥1 500 g <1 500 g
ANSs No ANSs p-value ANSs No ANSs p-value
Birth weight (g), mean (SD) 1 633.8 (84.7) 1 656.8 (88.2) 0.002 1 129.7 (234.2) 1 105.7 (250.6) 0.063
Gestational age (wk), mean (SD) 32.0 (1.6) 32.7 (2.3) <0.001 29.1 (2.3) 29.0 (2.8) 0.531
Duration of CPAP (d), median (IQR) 1 (0) 1 (1) 0.164 2 (3) 2 (2) 0.440
Duration of ventilation (d), median (IQR) 8 (13) 4 (3) 0.069 5 (9) 5 (6) 0.608
Duration of stay (d), median (IQR) 10 (9) 9 (9) 0.002 30 (28) 26 (31) 0.001
ANSs = antenatal corticosteroids; CPAP = continuous positive airway pressure; SD = standard deviation; IQR = interquartile range.
Table 4. Logistic regression for significant variables in 
neonates weighing ≥1 500 g exposed to ANSs
Variable OR 95% CI p-value
Antenatal care 2.132 1.157 - 3.921 0.015
Vaginal delivery 0.656 0.436 - 0.987 0.043
Maternal hypertension 2.008 1.305 - 3.096 0.002
Birth weight 0.998 0.996 - 1.000 0.034
Gestational age 0.826 0.754 - 0.906 <0.001
ANSs = antenatal corticosteroids; OR = odds ratio; CI = confidence interval.
Table 5. Logistic regression for significant variables in 
neonates weighing <1 500 g exposed to ANSs
Variable OR 95% CI p-value
Antenatal care 3.086 1.953 - 4.878 <0.001
Vaginal delivery 0.705 0.508 - 0.980 0.038
Multiple gestation 0.493 0.334 - 0.728 <0.001
Resuscitation at birth 0.581 0.427 - 0.791 0.001
PDA 0.462 0.290 - 0.736 0.001
Duration of stay 1.009 1.002 - 1.016 0.012
ANSs = antenatal corticosteroids; PDA = patent ductus arteriosus; OR = odds ratio;  
CI = confidence interval. 
